Imipenem-Cilastatin — Membership Pricing
Imipenem-Cilastatin is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Imipenem-Cilastatin Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $66.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Imipenem-Cilastatin
Imipenem-Cilastatin is a prescription medication. Ask your doctor if Imipenem-Cilastatin is right for you.
How to Check Imipenem-Cilastatin Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Imipenem-Cilastatin at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Infections
What Imipenem-Cilastatin is approved for (FDA label)
Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: • Lower respiratory tract infections. ( 1.1 ) • Urinary tract infections. ( 1.2 ) • Intra-abdominal infections. ( 1.3 ) • Gynecologic infections. ( 1.4 ) • Bacterial septicemia. ( 1.5 ) • Bone and joint infections. ( 1.6 ) • Skin and skin structure infections. ( 1.7 ) • Endocarditis. ( 1.8 ) Limitations of Use: • Imipenem and Cilastatin for Injection, USP is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ).
Source: Read the full FDA label on DailyMed. Label effective date: January 16, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Imipenem-Cilastatin (FDA label)
Imipenem and Cilastatin for Injection, USP is a sterile powder mixture for reconstitution in single-dose vials containing: • 500 mg imipenem (anhydrous equivalent) and 500 mg cilastatin (free acid equivalent) For Injection: Imipenem and Cilastatin for Injection, USP is a sterile powder mixture for reconstitution in single-dose containers including vials containing: • 500 mg imipenem (anhydrous equivalent) and 500 mg cilastatin (free acid equivalent) (3)
Source: FDA prescribing information (DailyMed). Set ID: 46f54df9-5afe-430c-aa19-0d84c2044b0b. SPL document ID: 6bfcc077-8c32-4c7e-abaa-f17eb2084231. Label effective date: January 16, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Imipenem-Cilastatin (FDA label)
The following serious adverse reactions are described in greater detail in the Warnings and Precautions section. • Hypersensitivity Reactions [see Warnings and Precautions (5.1) ] • Seizure Potential [see Warnings and Precautions (5.2) ] • Increased Seizure Potential Due to Interaction with Valproic Acid [see Warnings and Precautions (5.3) ] • Clostridioides difficile -Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4) ] • Development of Drug-Resistant Bacteria [see Warnings and Precautions (5.5) ] • The most frequently occurring adverse reactions (≥ 0.2%) in adults were phlebitis, nausea, diarrhea, vomiting, rash, pain injection site, fever, hypotension, seizures, erythema at injection site, dizziness, pruritus, vein induration, urticaria, somnolence ( 6.1 ).
Source: FDA prescribing information (DailyMed). Set ID: 46f54df9-5afe-430c-aa19-0d84c2044b0b. SPL document ID: 6bfcc077-8c32-4c7e-abaa-f17eb2084231. Label effective date: January 16, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Imipenem-Cilastatin (FDA label)
Imipenem and cilastatin for injection is contraindicated in patients who have shown hypersensitivity to any component of this product. • Known hypersensitivity to any component of imipenem and cilastatin for injection (4)
Source: FDA prescribing information (DailyMed). Set ID: 46f54df9-5afe-430c-aa19-0d84c2044b0b. SPL document ID: 6bfcc077-8c32-4c7e-abaa-f17eb2084231. Label effective date: January 16, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Imipenem-Cilastatin (FDA label)
• Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. If an allergic reaction to imipenem and cilastatin for injection occurs, discontinue the drug immediately ( 5.1 ). • Seizure Potential: Seizures and other CNS adverse reactions, such as confusional states and myoclonic activity, have been reported during treatment with imipenem and cilastatin for injection. If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of imipenem and cilastatin for injection re-examined to determine whether it should be decreased, or the antibacterial drug discontinued ( 5.2 ). • Increased Seizure Potential Due to Interaction with Valproic Acid: Co-administration of imipenem and cilastatin for injection, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations.
Source: FDA prescribing information (DailyMed). Set ID: 46f54df9-5afe-430c-aa19-0d84c2044b0b. SPL document ID: 6bfcc077-8c32-4c7e-abaa-f17eb2084231. Label effective date: January 16, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Imipenem-Cilastatin (FDA label)
• Ganciclovir: Generalized seizures have been reported in patients who received ganciclovir. Do not co-administer unless benefit outweighs risk ( 7.1 ). • Probenecid: Concomitant administration of imipenem and cilastatin for injection and probenecid results in increases in the plasma level and half-life of imipenem. Concomitant administration is not recommended ( 7.2 ). • Valproic acid/divalproex sodium: Concomitant use with imipenem and cilastatin for injection is generally not recommended. Consider other antibacterial drugs to treat infections in patients whose seizures are well-controlled on valproic acid or divalproex sodium ( 5.3 , 7.3 ). 7.1 Ganciclovir Generalized seizures have been reported in patients who received ganciclovir and imipenem and cilastatin for injection.
Source: FDA prescribing information (DailyMed). Set ID: 46f54df9-5afe-430c-aa19-0d84c2044b0b. SPL document ID: 6bfcc077-8c32-4c7e-abaa-f17eb2084231. Label effective date: January 16, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.